{
    "title": "Biogen shares soar on landmark Alzheimer's data, lift rivals",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11258237/Biogen-Eisai-stocks-soar-landmark-Alzheimers-data-lifting-rivals.html",
    "date": "2022-09-28",
    "keywords": [
        "drug",
        "trial",
        "biogen",
        "disease",
        "analyst",
        "grover",
        "success",
        "eisai",
        "win",
        "year",
        "lecanemab",
        "failure",
        "inc",
        "market",
        "capitalization",
        "wednesday",
        "surprise",
        "tuesday",
        "victory",
        "search",
        "treatment",
        "memoryrobbing",
        "stock",
        "track",
        "ltd",
        "limit",
        "progress",
        "brainwasting",
        "placebo",
        "bestcase",
        "scenario",
        "program",
        "appear",
        "ambiguity",
        "skorney",
        "bmo",
        "evan",
        "seigerman",
        "protein",
        "plaque",
        "beta",
        "progression",
        "brain",
        "hypothesis",
        "blow",
        "panel",
        "aduhelm",
        "ability",
        "decline",
        "boost",
        "eisais",
        "hope",
        "gantenerumab",
        "donanemab",
        "anything",
        "return",
        "investment",
        "chancellor",
        "healthcare",
        "corporation",
        "plc",
        "reporting",
        "london",
        "mishra",
        "bengaluru",
        "editing",
        "jason",
        "samuel"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}